Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Lundbeck

Market Cap 40.47B 6.21B 5.41B 4.99B 4.69B 8.78B 586B 8.84B 59.38B 23.06B 289B 23.33B 22.83B 1,000B P/E 2026 *
9.34x
P/E 2027 * 9.14x
Enterprise Value 44.57B 6.84B 5.96B 5.5B 5.17B 9.67B 645B 9.74B 65.4B 25.4B 318B 25.69B 25.14B 1,102B EV / Sales 2026 *
1.73x
EV / Sales 2027 * 1.57x
Free-Float
30.76%
Yield 2026 *
3.5%
Yield 2027 * 3.58%
1 day+0.28%
1 week+0.14%
Current month-0.54%
1 month+4.57%
3 months+9.42%
6 months+3.68%
Current year+1.10%
1 week 35.65
Extreme 35.65
36.85
1 month 35
Extreme 35
37.55
Current year 31.4
Extreme 31.4
39.9
1 year 28.5
Extreme 28.5
39.9
3 years 23.3
Extreme 23.3
41.7
5 years 21.94
Extreme 21.935
41.7
10 years 21.94
Extreme 21.935
41.7
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+2.38%+0.14% - - 6.21B
+0.15%-4.64%+2.98%+84.79% 87.88B
-1.99%+0.28%+34.08%+143.04% 51.94B
-1.78%+2.60%-14.81%+224.71% 22.71B
-1.24%-2.03%-9.60%-26.78% 7.96B
+2.31%-2.71%-31.28%-32.89% 7.35B
-2.73%-2.50%-10.78%-36.88% 6.52B
+0.87%-1.47%-2.84%+17.56% 5.15B
+1.47%+2.11%-5.48%-13.58% 3.56B
+2.15%-3.37%+9.30%+9.58% 3.23B
Average -0.44%-0.72%-3.16%+41.06% 21.81B
Weighted average by Cap. -2.29%+0.72%+6.70%+98.62%

Financials

2026 *2027 *
Net sales 25.7B 3.95B 3.44B 3.17B 2.98B 5.58B 372B 5.62B 37.72B 14.65B 183B 14.82B 14.5B 635B 25.74B 3.95B 3.44B 3.17B 2.99B 5.59B 372B 5.62B 37.76B 14.67B 184B 14.83B 14.52B 636B
Net income 4.71B 723M 630M 581M 546M 1.02B 68.17B 1.03B 6.91B 2.68B 33.6B 2.72B 2.66B 116B 4.81B 738M 643M 593M 558M 1.04B 69.57B 1.05B 7.05B 2.74B 34.28B 2.77B 2.71B 119B
Net Debt 4.1B 629M 548M 505M 475M 889M 59.31B 896M 6.01B 2.34B 29.23B 2.36B 2.31B 101B -30.08M -4.62M -4.02M -3.71M -3.49M -6.53M -435M -6.57M -44.14M -17.14M -215M -17.34M -16.97M -744M
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
20/06/26 36.60 kr +2.38% 300,432
18/06/26 35.75 kr -0.28% 92,152
17/06/26 35.85 kr -0.14% 22,894
16/06/26 35.90 kr -1.78% 56,002
15/06/26 36.55 kr 0.00% 62,560
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
42.10DKK
Average target price
47.21DKK
Spread / Average Target
+12.13%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!